drugset
Drugs / Anakinra
last change 10 days ago re-read 9 days ago

Anakinra

also known as Kineret · r-metHuIL-1ra · ANA · IL-1Ra · Alta-2530 · AMG 719 · Anakinra: kineret · ANK · +5 more

Protein / enzyme biologic targets IL1B, IL1R1 via inhibition

Developed for
COVID-19 · heart failure · type 2 diabetes mellitus · cytokine release syndrome · Kawasaki disease · rheumatoid arthritis · adult-onset Still disease · macrophage activation syndrome
+100 more · plasma cell myeloma · familial Mediterranean fever · infectious disease with sepsis · systemic-onset juvenile idiopathic arthritis · type 1 diabetes mellitus · acute myocardial infarction · acute myocarditis · asthma · autoimmune inner ear disease · end stage renal failure · gout · hidradenitis suppurativa · high grade B-cell lymphoma · hypoglycemia · pancreatic adenocarcinoma · pericarditis · primary mediastinal large B-cell lymphoma · systolic heart failure · acute respiratory distress syndrome · alcoholic hepatitis · allergic asthma · amyotrophic lateral sclerosis · atopic eczema · autoimmune disease · B-cell chronic lymphocytic leukemia · breast cancer · cancer of unknown primary site · cardiac sarcoidosis · central nervous system malformation · chronic granulomatous disease · colorectal cancer · connective tissue disorder · Cushing syndrome · cystic fibrosis · dengue disease · dermatomyositis · diabetes mellitus · endometriosis · familial cold autoinflammatory syndrome · glucose intolerance · hereditary hemochromatosis · HIV infectious disease · hyperinsulinism · immune system disorder · inclusion body myositis · indolent plasma cell myeloma · inflammatory disease · intracerebral hemorrhage · ischemic stroke · long COVID-19 · melanoma · Meniere disease · metabolic syndrome X · metastatic malignant neoplasm · mucopolysaccharidosis type 3 · multiple sclerosis · myalgic encephalomeyelitis/chronic fatigue syndrome · nervous system disorder · neurogenic arthropathy · non-small cell lung carcinoma · obesity disorder · osteoarthritis · osteoarthritis, knee · palmoplantar pustulosis · pancreas disorder · pancreatic ductal adenocarcinoma · pneumonia · polyarticular juvenile rheumatoid arthritis · polycystic ovary syndrome · prediabetes syndrome · psoriasis 14, pustular · pulmonary arterial hypertension · pulmonary hypertension · rectal cancer · retinal edema · sensorineural hearing loss disorder · Sneddon syndrome · ST-elevation myocardial infarction · sudden sensorineural hearing loss · temporal arteritis · traumatic brain injury · triple-negative breast carcinoma · urticaria · uveitis · viral respiratory tract infection · allergic contact dermatitis · blepharitis · coronary artery disorder · COVID-19–associated multisystem inflammatory syndrome in children · diastolic heart failure · dumping syndrome · febrile infection-related epilepsy syndrome · hypogonadism, male · idiopathic recurrent pericarditis · multiple organ dysfunction syndrome · new-onset refractory status epilepticus · primary bacterial infectious disease · pulmonary immaturity · respiratory failure · Sjogren syndrome
Investigated by
Virginia Commonwealth University · Swedish Orphan Biovitrum · Assistance Publique - Hôpitaux de Paris · Radboud University Medical Center · Amgen · Hellenic Institute for the Study of Sepsis
+130 more · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · University Hospital, Basel, Switzerland · American Heart Association · Baylor Research Institute · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of Neurological Disorders and Stroke (NINDS) · University of California, San Diego · University of North Carolina, Chapel Hill · Andrea Vambutas · Assistance Publique Hopitaux De Marseille · M.D. Anderson Cancer Center · Mayo Clinic · National Institutes of Health (NIH) · Rigshospitalet, Denmark · Steno Diabetes Center Copenhagen · Tigermed Consulting Co., Ltd · University of Alabama at Birmingham · Adel Helmy · Alan Prossin · Alberta Innovates Health Solutions · Asst Degli Spedali Civili Di Brescia · Atlantic Provinces Dermatology Association · Australian and New Zealand Intensive Care Research Centre · Azienda Sanitaria-Universitaria Integrata di Udine · Beijing Tiantan Hospital · Berry Consultants · Boston Children's Hospital · CMIC Co, Ltd. Japan · Cale Jacobs, PhD · Cambridge University Hospitals NHS Foundation Trust · Cedars-Sinai Medical Center · Centre Georges Francois Leclerc · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Charite University, Berlin, Germany · Children's Medical Center Dallas · Cure Sanfilippo Foundation · Dr. David Spaner · Duke University · Dutch Cancer Society · Dutch Heart Foundation · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Fred Hutchinson Cancer Center · Fundacion Miguel Servet · Gaslini Institute · Global Coalition for Adaptive Research · Goethe University · Heidelberg University · Helse Stavanger HF · Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam · Hudson Institute of Medical Research · Hôpital d'instruction des armées Sainte-Anne · INSERM CIC-P 1415, University Hospital Center of Tours · IRCCS Burlo Garofolo · Intensive Care National Audit & Research Centre · Johns Hopkins University · Jonsson Comprehensive Cancer Center · Juno Therapeutics, a Subsidiary of Celgene · Juvenile Diabetes Research Foundation · Jyväskylä Central Hospital · Kantonsspital Baden · Karolinska Institutet · Kevin McNerney · Kite, A Gilead Company · Kuopio University Hospital · Lovisenberg Diakonale Hospital · Lynda E Polgreen · Mack Mitchell · Marc Donath · Massachusetts General Hospital · Max Planck Institute for Infection Biology · Medical Research Institute of New Zealand · Memorial Sloan Kettering Cancer Center · Meyer Children's Hospital IRCCS · all 136 on the full record

Regulatory milestones approvals, filings & regulatory actions · 10 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed COVID-19 1 milestone
Filed EU (EMA) Kineret COVID-19 —

“In July, Kineret® was submitted to EMA with a proposed indication for the treatment of coronavirus disease 2019 (COVID-19)” sobi.com ↗
Filed cryopyrin-associated periodic syndrome 1 milestone
Filed EU (EMA) Kineret cryopyrin-associated periodic syndrome 2012-11-19

“filed an application for an EU Marketing Authorization with the European Medicines Agency (EMA) for Kineret® (anakinra) for the indication of cryopyrin associated periodic...” sobi.com ↗
Filed neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 1 milestone
Filed US (FDA) Kineret neonatal-onset severe multisystemic autoinflammatory disease with increased IL18 2012-07-06

“filed an application for Kineret® (anakinra) for the indication of neonatal-onset multisystem inflammatory disease (NOMID) with the Federal Drug Administration” sobi.com ↗
Approved Indication not stated 3 milestones
Label expansions (5) US (FDA) KINERET — 2003-08-22 – 2020-12-18 fda.gov ↗
Approved EU (EMA) Kineret — 2002-03-08 europa.eu ↗
Approved US (FDA) KINERET — 2001-11-14 fda.gov ↗

Trials 134 · started per year

today
US approved 2001
EU approved 2002
1
1
2
4
2
2
1
2
2
2
7
6
5
8
4
9
9
3
9
18
8
7
6
2
4
9
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 05 trials
Phase 0 NCT07410312 Jul 2026 → Aug 2027 expected — Northwestern University Not yet recruiting No outcome recorded
Phase 0 NCT03991520 Jun 2020 → Jan 2022 endometriosis University of California, San Diego Unknown No outcome recorded
Phase 0 NCT04747847 Jun 2019 → Aug 2022 Kawasaki disease University of California, San Diego Completed No outcome recorded
Phase 0 NCT02550327 Jan 2016 → Jun 2021 pancreatic adenocarcinoma Baylor Research Institute Completed No outcome recorded
Phase 0 NCT04136028 Sep 2015 → Jan 2019 chronic granulomatous disease Federal Research Institute of Pediatric Hematology, Oncology and Immunology Completed No outcome recorded
Phase 115 trials
Phase 1 NCT07838974 Nov 2026 → Nov 2029 expected melanoma University of Southern California Not yet recruiting No outcome recorded
Phase 1 NCT06062966 Feb 2024 → Jun 2026 heart failure Virginia Commonwealth University Completed No outcome recorded
Phase 1 NCT04942626 Aug 2021 → Dec 2024 rectal cancer Goethe University Completed No outcome recorded
Phase 1 NCT05074485 Jul 2021 → May 2026 — Alan Prossin Unknown No outcome recorded
Phase 1 NCT04691765 May → Dec 2021 B-cell chronic lymphocytic leukemia Dr. David Spaner Unknown No outcome recorded
Phase 1 NCT02780583 May 2016 → Mar 2023 macrophage activation syndrome University of Alabama at Birmingham Terminated No outcome recorded Stop: Business
Phase 1 NCT02492750 Apr 2016 → Jun 2019 indolent plasma cell myeloma Mayo Clinic Completed No outcome recorded
Phase 1 NCT03057028 Apr 2016 → Jun 2018 pulmonary arterial hypertension Virginia Commonwealth University Completed No outcome recorded
Phase 1 NCT02527460 Aug 2015 → Mar 2018 HIV infectious disease, nervous system disorder National Institute of Neurological Disorders and Stroke (NINDS) Terminated No outcome recorded
Phase 1 NCT02021422 Dec 2013 → Dec 2017 pancreatic ductal adenocarcinoma Baylor Research Institute Completed No outcome recorded
Phase 1/221 trials · 3 met primary
Phase 1/2 NCT06703216 Oct 2026 → Aug 2029 expected B-cell acute lymphoblastic leukemia, cytokine release syndrome, hemophagocytic syndrome Kevin McNerney Not yet recruiting No outcome recorded
Phase 1/2 NCT07503834 May 2026 → Nov 2028 expected pancreas disorder Nantes University Hospital Not yet recruiting No outcome recorded
Phase 1/2 NCT05280340 Feb 2022 → Mar 2024 overdue — Monash Medical Centre Active not recruiting No outcome recorded
Phase 1/2 NCT05013450 Sep 2021 → Sep 2025 overdue non-small cell lung carcinoma Thomas Marron Active not recruiting No outcome recorded
Phase 1/2 NCT03513458 Sep 2020 → Dec 2021 asthma University of North Carolina, Chapel Hill Withdrawn No outcome recorded
Phase 1/2 NCT04018755 Jan 2020 → Jul 2022 mucopolysaccharidosis type 3 Lynda E Polgreen Completed No outcome recorded
Phase 1/2 NCT04035109 Dec 2019 → Oct 2022 allergic asthma University of North Carolina, Chapel Hill Withdrawn No outcome recorded
Phase 1/2 NCT04025554 Oct 2019 → Oct 2023 multiple sclerosis National Institute of Neurological Disorders and Stroke (NINDS) Completed No outcome recorded
Phase 1/2 NCT03513471 Aug 2019 → Dec 2021 asthma University of North Carolina, Chapel Hill Withdrawn No outcome recorded
Phase 1/2 NCT03430011 Feb 2018 → Mar 2023 plasma cell myeloma Juno Therapeutics, a Subsidiary of Celgene Completed No outcome recorded
Phase 257 trials · 4 met primary · 6 missed
Phase 2 NCT07580079 Jul → Oct 2026 expected end stage renal failure, hypoglycemia, postgastrectomy syndrome Marc Donath Not yet recruiting No outcome recorded
Phase 2 NCT06381661 May 2026 → Jun 2028 expected infectious disease with sepsis Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 2 NCT07423975 Mar → Sep 2026 overdue ischemic stroke Beijing Tiantan Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07138898 Dec 2025 → Jan 2028 expected rheumatic disorder NYU Langone Health Recruiting No outcome recorded
Phase 2 NCT06710197 Mar 2025 → Feb 2026 triple-negative breast carcinoma University Health Network, Toronto Withdrawn No outcome recorded Stop: Enrollment
Phase 2 NCT05854251 Jun 2023 → May 2024 hyperinsulinism, prediabetes syndrome University Hospital, Basel, Switzerland Completed No outcome recorded
Phase 2 NCT05914454 May 2023 → Jun 2025 acute respiratory distress syndrome Azienda Sanitaria-Universitaria Integrata di Udine Unknown No outcome recorded
Phase 2 NCT05611710 Jan 2023 → Oct 2025 overdue cytokine release syndrome, dengue disease, macrophage activation syndrome Oxford University Clinical Research Unit, Vietnam Active not recruiting No outcome recorded
Phase 2 NCT03925194 Dec 2022 → Jun 2025 cystic fibrosis Heidelberg University Terminated No outcome recorded Stop: Business
Phase 2 NCT04834388 Aug 2022 → Sep 2025 intracerebral hemorrhage Radboud University Medical Center Unknown No outcome recorded
Phase 2/310 trials · 5 missed
Phase 2/3 NCT05926505 Sep 2023 → Mar 2028 expected long COVID-19 Hellenic Institute for the Study of Sepsis Recruiting No outcome recorded
Phase 2/3 NCT04443881 May 2020 → Mar 2021 COVID-19 Fundacion Miguel Servet Completed Missed primary
Phase 2/3 NCT03018834 May 2017 → Jun 2021 acute myocarditis Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 2/3 NCT01950299 Jul 2014 → Dec 2018 acute myocardial infarction Virginia Commonwealth University Completed No outcome recorded
Phase 2/3 NCT02108210 Jun 2014 → Dec 2015 myalgic encephalomeyelitis/chronic fatigue syndrome Radboud University Medical Center Completed Missed primary
Phase 2/3 NCT01936909 Feb 2014 → Sep 2016 heart failure Virginia Commonwealth University Completed Missed primary
Phase 2/3 NCT01936844 Feb 2014 → May 2015 heart failure Virginia Commonwealth University Completed No outcome recorded
Phase 2/3 NCT01809132 Sep 2013 → Oct 2018 alcoholic hepatitis Mack Mitchell Completed Missed primary
Phase 2/3 NCT00711503 Jan 2009 → Jan 2012 type 1 diabetes mellitus Steno Diabetes Center Copenhagen Completed Missed primary
Phase 2/3 NCT01165008 Sep 2003 → Sep 2008 dermatomyositis, inclusion body myositis Karolinska Institutet Completed No outcome recorded
Phase 316 trials · 4 met primary · 1 missed
Phase 3 NCT07371689 Feb 2026 → Dec 2029 expected acute myocarditis Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 3 NCT06336733 Jun 2024 → Dec 2026 expected familial Mediterranean fever Assistance Publique - Hôpitaux de Paris Recruiting No outcome recorded
Phase 3 NCT04656184 Oct 2023 → Mar 2027 expected Kawasaki disease Assistance Publique - Hôpitaux de Paris Recruiting No outcome recorded
Phase 3 NCT05805930 Jun 2023 → Jun 2025 pericarditis Gaslini Institute Unknown No outcome recorded
Phase 3 NCT05814159 Aug 2022 → Dec 2025 overdue adult-onset Still disease, systemic-onset juvenile idiopathic arthritis Swedish Orphan Biovitrum Active not recruiting No outcome recorded
Phase 3 NCT04680949 Dec 2020 → Mar 2021 COVID-19 Hellenic Institute for the Study of Sepsis Completed Met primary
Phase 3 NCT04424056 Sep 2020 → Sep 2022 COVID-19 Assistance Publique Hopitaux De Marseille Unknown No outcome recorded
Phase 3 NCT04362111 Aug 2020 → Dec 2021 COVID-19, cytokine release syndrome University of Alabama at Birmingham Completed No outcome recorded
Phase 3 NCT04364009 Apr → Oct 2020 COVID-19 University Hospital, Tours Terminated No outcome recorded
Phase 3 NCT03265132 Sep 2017 → Feb 2019 adult-onset Still disease, systemic-onset juvenile idiopathic arthritis Swedish Orphan Biovitrum Terminated Met primary
Phase 46 trials
Phase 4 NCT06666335 Mar 2026 → Aug 2027 familial Mediterranean fever Swedish Orphan Biovitrum Withdrawn No outcome recorded Stop: Business
Phase 4 NCT07706868 Sep 2025 → Sep 2028 adult-onset Still disease, systemic-onset juvenile idiopathic arthritis Swedish Orphan Biovitrum Withdrawn No outcome recorded Stop: Business
Phase 4 NCT06697431 Apr 2025 → Apr 2026 overdue Kawasaki disease Meyer Children's Hospital IRCCS Not yet recruiting No outcome recorded
Phase 4 NCT01997138 Mar 2016 → Jan 2018 — Oslo University Hospital Withdrawn No outcome recorded Stop: Enrollment
Phase 4 NCT02236481 Jul 2013 → Dec 2017 rheumatoid arthritis, type 2 diabetes mellitus Prof. Roberto Giacomelli Terminated No outcome recorded
Phase 4 NCT00111410 ? → Nov 2003 rheumatoid arthritis Amgen Completed No outcome recorded
Phase not applicable4 trials · 1 met primary
— NCT02916355 Aug 2016 → Apr 2017 obesity disorder University Hospital, Basel, Switzerland Completed No outcome recorded
— NCT02310009 Dec 2014 → Jun 2015 type 2 diabetes mellitus Rigshospitalet, Denmark Withdrawn No outcome recorded
— NCT01542502 Feb 2012 → Jun 2013 heart failure Virginia Commonwealth University Completed Met primary
— NCT01285232 Jan 2011 → Mar 2012 glucose intolerance, type 2 diabetes mellitus Radboud University Medical Center Unknown No outcome recorded
Comparator or background therapy42 trials
Phase 0 NCT03968913 Comparator Sep 2021 → Jan 2027 expected — University of California, Los Angeles Recruiting No outcome recorded
Phase 1 NCT07600190 Comparator Nov 2026 → Jan 2029 expected chronic asthma University of North Carolina, Chapel Hill Not yet recruiting No outcome recorded
Phase 1 NCT04544813 Comparator Oct 2020 → May 2021 — Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT04227275 Background Nov 2019 → Nov 2022 castration-resistant prostate carcinoma Tceleron Therapeutics, Inc. Terminated No outcome recorded
Phase 1 NCT02175056 Comparator May 2014 → Jan 2015 — Handok Inc. Completed No outcome recorded

News releases announcing trial results or a regulatory action · 16

DateIssuerRelease
2022-11-10 Sobi, Inc. Regulatory Kineret® authorised for emergency use by FDA for the treatment of COVID-19 related pneumonia sobi.com ↗
Sobi® today announced that the US Food and Drug Administration has granted Emergency Use Authorisation (EUA) for the use of Kineret® (anakinra) for the treatment of coronavirus disease 2019 (COVID-19) in hospitalised adults with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure.
2021-12-16 Sobi, Inc. Regulatory Kineret® (anakinra) receives positive opinion from the CHMP for treatment of patients with COVID-19 pneumonia sobi.com ↗
EMA has recommended approval for use of Kineret in COVID-19 to the European Commission which will issue a final decision.
2021-09-03 Sobi, Inc. Results Nature Medicine publishes phase 3 anakinra study results in patients with COVID-19 pneumonia sobi.com ↗
Early treatment with anakinra showed considerable efficacy and reduced risk of disease progression and death by 64 percent, according to day 28 results from the SAVE-MORE study.
2021-05-20 Sobi, Inc. Results Early use of anakinra reduces risk of mortality for patients with COVID-19 pneumonia, reduces ICU admission and increases likelihood of full recovery sobi.com ↗
SAVE-MORE found that early and targeted use of anakinra, in addition to current SOC, showed a 55% relative reduction in mortality and near threefold benefit in preventing progression to severe respiratory failure (SRF) in hospitalised COVID-19 patients with poor prognosis.
2021-05-03 Sobi, Inc. Results Sobi and Hellenic Institute for the Study of Sepsis: anakinra improved overall clinical outcomes by 64% in hospitalised patients with COVID-19 pneumonia sobi.com ↗
Analysis of the primary end point, the comparative 11-point WHO Clinical Progression ordinal Scale (CPS) [i] , at day 28 demonstrated significant improvement in patients receiving standard-of-care treatment plus anakinra vs patients receiving standard-of-care plus placebo (Odds Ratio 0.36, p < 0.001).
2021-02-16 Sobi, Inc. Regulatory Kineret® (anakinra) approved in Russia for the treatment of CAPS sobi.com ↗
Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the Ministry of Health of the Russian Federation has approved Kineret (anakinra) for the treatment of Cryopyrin associated periodic syndromes (CAPS).
2018-10-03 Sobi, Inc. Results Results from the anaGO study - a phase 2 study with anakinra in patients with acute gout sobi.com ↗
Swedish Orphan Biovitrum AB (publ) (Sobi™) releases the primary efficacy results from the phase 2 study with anakinra in patients with acute gout – the anaGO study.
2018-04-11 Sobi, Inc. Regulatory Kineret® (anakinra) approved in the EU for the treatment of Still's disease sobi.com ↗
Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the European Commission (EC) has approved an extension of the indication for Kineret (anakinra) to include the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), in all 28 European Union (EU) member states.
2018-02-23 Sobi, Inc. Regulatory Kineret® (anakinra) receives a positive opinion from CHMP for the treatment of Still's disease sobi.com ↗
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for anakinra for the treatment of Still’s disease.
2017-05-30 Sobi, Inc. Regulatory Kineret® approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) sobi.com ↗
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Health Canada has approved Kineret® (anakinra) for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) in adults, adolescents, children and infants aged eight months and older with a body weight of 10 kg or above.
2013-11-20 Sobi, Inc. Regulatory Sobi receives approval for Kineret® for treatment of rare disease CAPS sobi.com ↗
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the European Commission (EC) has approved Kineret (anakinra) for the treatment of Cryopyrin- Associated Periodic Syndromes (CAPS).
2013-09-23 Sobi, Inc. Regulatory Sobi receives positive CHMP opinion for Kineret® for treatment of rare disease CAPS sobi.com ↗

All press releases naming this drug 24 releases

DateIssuerRelease

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 180 sources stand behind the page.

FieldValueCited text
Known as anakinra “The primary purpose of this study is to determine whether giving injections of anakinra is a safe and well tolerated treatment to give as an adjunct to standard prescribed...” NCT02780583 ↗
170

“"Kineret" (INN: Anakinra) neutralizes the biological activity of interleukin-1α (IL-1α) and interleukin-1β (IL-1β) by the concurrent inhibition of binding to interleukin-1...” NCT04136028 ↗

“Efficacy and Safety of ANAkinra During Adult " COVID-19 " With Aggravating Respiratory Symptoms: a Multicenter Open-label Controlled Randomized Trial” NCT04364009 ↗

“34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks” PMID 17429083 ↗ Apr 2007

“Recombinant human interleukin-1 receptor antagonist (anakinra) is an anti-inflammatory with efficacy in animal models of stroke.” PMID 37452707 ↗ Jul 2023

“Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.” NCT04942626 ↗

“Product: Kineret (anakinra) Protocol title: The Use of Kineret (anakinra) in the Treatment of Familial Cold Urticaria (FCU)” NCT00214851 ↗

“receive either the IL–1 receptor antagonist IL-1Ra (anakinra) or placebo prior to an acute treadmill exercise.” PMID 26448147 ↗ Oct 2015

“Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days” NCT04374539 ↗

“Anakinra 2.5%” NCT00681109 ↗

NCT03578497 ↗

Show 160 more sources
Known as Alta-2530 ChEMBL registry synonym — accepted as the source's own label CHEMBL1201570 ↗
Known as AMG 719 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00038298 ↗
Known as ANA “Anakinra (ANA) is a recombinant human decoy IL-1Ra and therefore blocks IL-1α and IL-1β.” NCT04341584 ↗
1

“We assessed the safety of Anakinra (ANA), an IL-1 receptor antagonist, in ALS patients.” PMID 26444282 ↗ Oct 2015
Known as Anakinra: kineret “Anakinra: kineret” NCT01802970 ↗
Known as ANK “Efficacy and tolerance of anakinra (ANK) in the treatment of giant cell arteritis (GCA) need to be assessed.” PMID 40483523 ↗ Jun 2025
Known as Antril ChEMBL registry synonym — accepted as the source's own label CHEMBL1201570 ↗
Known as IL-1Ra “receive either the IL–1 receptor antagonist IL-1Ra (anakinra) or placebo prior to an acute treadmill exercise.” PMID 26448147 ↗ Oct 2015
1

“Anakinra (IL-1Ra)” NCT00635154 ↗
Known as Interleukin-1 receptor antagonist anakinra ChEMBL registry synonym — accepted as the source's own label CHEMBL1201570 ↗
Known as Kineret “Anakinra is a commercially available product (Kineret™) approved for the treatment of rheumatoid arthritis; it is a replica of a naturally occurring protein called Il-1...” NCT02780583 ↗
31

“Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100...” NCT05174507 ↗

“Patients on corticosteroids (plus conventional therapy) will be randomized to receive anakinra (Kineret®), or one of the following: methotrexate, azathioprine, leflunomide,...” NCT01033656 ↗

“The primary end point was change in morning cortisol from baseline to after the administration of the IL-1 receptor antagonist (anakinra/Kineret®, total dose 3 × 100 mg).” PMID 28324042 ↗ May 2017

“Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra).” NCT07580079 ↗

“100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.” NCT02310009 ↗

“Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.” NCT04942626 ↗

“Anakinra/Kineret\[registered\] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)” NCT01441076 ↗

“Effects of Anakinra (Kineret) in Subjects With Corticosteroid-Resistant/Intolerant Meniere's Disease” NCT03587701 ↗

“A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis” NCT01122914 ↗

“Anakinra (Kineret) has been shown to treat and cure refractory and recurrent pericarditis.” NCT03224585 ↗

Show 21 more sources
Known as Kineret (anakinra) “Kineret® (anakinra)” NCT01566201 ↗
Known as metHuIL-1ra “Intra-articular metHuIL-1ra (anakinra)” NCT00110916 ↗
Known as Osp-101 ChEMBL registry synonym — accepted as the source's own label CHEMBL1201570 ↗
Known as r-metHuIL-1ra “A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open-label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single,...” NCT00037648 ↗
5

“Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100...” NCT05174507 ↗

“Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra).” NCT07580079 ↗

“Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB)” NCT04227769 ↗

“Anakinra (r-metHuIL-1ra)” NCT00537667 ↗

“Anakinra (r-metHuIL-1ra)” NCT00111410 ↗
Action Inhibit “blocks a substance called IL-1” NCT00069329 ↗
Modality Protein / enzyme biologic “100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist)” PMID 17429083 ↗ Apr 2007
Route Subcutaneous “Subcutaneous Injections” NCT00037648 ↗
Target IL1R1 “anakinra (IL-1R1receptor antagonist)” NCT02390596 ↗